<DOC>
	<DOCNO>NCT02488512</DOCNO>
	<brief_summary>This prospective , single arm , single centre open-label , phase II study relapse refractory DLBCL MCL non-Hodgkin 's lymphoma ( NHL ) , suitable therapy , include HDCT , patient relapse high-dose chemotherapy ( HDCT ) autologous stem-cell transplantation ( ASCT ) , treat peptide receptor radionuclide therapy 90Y-Dotatoc . Each patient receive maximum cumulative 90Y-DOTATOC activity 11.1 GBq ( 300 mCi ) , divide 4 cycle ( 1.8 - 2.8 gigabequerel ( GBq ) cycle ) interval 6 - 8 week cycle . The 90Y-DOTATOC slowly infuse intravenously . 35 patient enrol 36 month two stage ( 18 patient first stage , 2 few patient show objective response , study close ) .</brief_summary>
	<brief_title>Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc Relapsed/Refractory Diffuse Large B Cell Mantle Cell Lymphomas</brief_title>
	<detailed_description>PEPTIDE RECEPTOR RADIONUCLIDE THERAPY ( PRRT ) WITH 90Y-DOTATOC IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL AND MANTLE CELL LYMPHOMAS . This prospective , single arm , open-label , phase II study . It estimate maximum 35 patient enrol 36 month ; treatment efficacy test 18 patient first stage , 2 few patient show objective response , study close ; &gt; 2 objective response observe , total 35 patient enrol . Follow period 48 month . Single-center The primary objective evaluation objective response rate ( ORR ) . Y-PRRT relapse refractory DLBCl MCL NHL , suitable therapy , include HDCT , patient relapse HDCT ASCT . The secondary objective toxicity ( acute late ) , progression free survival , overall survival Quality life . 35 patient enrol 36 month two stage ( 18 patient first stage , 2 few patient show objective response , study close ) . Each patient receive maximum cumulative 90Y-DOTATOC activity 11.1 GBq ( 300 mCi ) , divide 4 cycle ( 1.8 - 2.8 GBq cycle ) interval 6 - 8 week cycle . The 90Y-DOTATOC slowly infuse intravenously . The study conduct follow Optimal Two Stage Design assume true response probability : - H0 ( p0 ) &lt; =10 % - H1 ( p1 ) &gt; =30 % consider alpha=0.05 power=0.90 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Edotreotide</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>1 . Male Female , age &gt; 18 year . 2 . Histologically confirm relapsed refractory DLBCL MCL suitable treatment . 3 . Patients documented disease admit therapeutic phase diagnostic PET/CT 68GaDOTATOC image demonstrate significant uptake tumour ( SSRpositive tumour ) . 4 . Patients must least one bidimensional measurable lesion long axis &gt; 15 mm CT scan ( MRI allow CT scan perform ) , accord Cheson Criteria . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . 6 . Life expectancy least 3 month . 7 . Adequate cardiac function assess echocardiography ECG . 8 . Conserved hematological , liver renal parameter , particular : haemoglobin &gt; = 9 g/dL , absolute neutrophil count ( ANC ) &gt; = 1.5 x 109 /L , platelets &gt; = 100 x 109 /L , bilirubin ≤1.5 X UNL ( upper normal limit ) , Alanine aminotransferase ( ALT ) &lt; 2.5 X UNL ( &lt; 5 X UNL presence liver metastasis ) , creatinine &lt; 2 mg/dL 9 . Patients must receive treatment radiopeptides ( e.g . 111Inpentetreotide , 177LuDOTATATE , 131IMIBG ) . 10 . If female childbearing potential , agreement use adequate contraceptive method ( e.g. , oral contraceptive , condom , adequate barrier control , intrauterine contraceptive device , sterilization ) begin screen visit continue 3 month follow last treatment study drug . Negative serum pregnancy test female childbearing potential within 7 day start treatment . 1 . Pregnancy/breastfeeding ( pregnancy test old 7 day mandatory ) . 2 . Bone marrow invasion &gt; 25 % . 3 . Other concomitant neoplasm ( exclude situ basaliomas radically treat cervical cancer ) ; subject must free neoplasm least 3 year . All acute toxic effect prior therapy ( include surgery radiation therapy , chemotherapy ) must resolve grade &lt; = 1 accord National Cancer Institute Common Terminology Criteria Adverse Events Version 4.0 ( CTCAE ) . 4 . Evidence myelodysplastic syndrome hematologic diseases 5 . Patients treat chemotherapy therapeutic radiotherapy within 4 week . 6 . Participation another clinical trial investigational agent within 30 day prior study screen . 7 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 8 . Positive serology Hepatitis B ( HB ) define positive test Hepatitis B surface antigen ( HbsAg ) . In addition , negative HBsAg Hepatitis B core antibody ( HBcAb ) positive ( regardless HBsAb status ) , hepatitis B virus ( HBV ) DNA test perform positive subject exclude . Any patient HBcAb positivity receive anti viral prophylaxis study , accord procedure suggest local Hepatology service . 9 . History allergic reaction attribute compound similar chemical biologic composition . 10 . Previous autologous stem cell transplant last 2 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Relapsed/refractory diffuse large b cell</keyword>
	<keyword>Relapsed/refractory mantle cell lymphoma</keyword>
	<keyword>DLBCL</keyword>
	<keyword>MCL</keyword>
	<keyword>90Y-DOTATOC</keyword>
	<keyword>SSR-positive tumour</keyword>
</DOC>